Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain—differences between regional pharmacovigilance centres and pharmaceutical industry
- 23 May 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (8) , 1175-1181
Abstract
Purpose The aim of this study is to compare the completeness of relevant structured fields such as age, sex, drug and reaction start dates, time to onset, outcome and drug indication, in serious spontaneous cases reported in Spain depending on whether they have been collected by regional pharmacovigilance centres or by the marketing authorization holders. Methods We analyzed the completeness of key variables for causality assessment related to the patient, the reaction and the suspected drug in all serious cases spontaneously reported and registered in the Spanish Pharmacovilance database, called FEDRA, from 1 January 2011 until 31 December 2018. The completeness scores were calculated according to the type of field and taking into account the VigiGrade tool. Cases were classified according to the reporting pathway, that is whether they were received and transmitted by marketing authorization holder or by regional pharmacovigilance centres. Results The completeness score of cases collected by regional pharmacovigilance centres was higher in all the studied variables. The main differences were found in drug and reaction start date, and time to onset. Conclusions This study shows a high completeness score in cases of suspected adverse reactions reported to the regional pharmacovigilance centres with regard to key elements for causality assessment, signal and duplicate detection. In contrast, marketing authorization holder cases show a low completeness score and a decreasing tendency in all the studied variables over the studied period.Keywords
This publication has 10 references indexed in Scilit:
- Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia—a restraint to the potentiality for signal detectionEuropean Journal of Clinical Pharmacology, 2017
- Good Signal Detection Practices: Evidence from IMI PROTECTDrug Safety, 2016
- Drug makers' adverse event reports are often incomplete, US report findsBMJ, 2015
- Pharmacovigilance in Spain2014
- Performance of Probabilistic Method to Detect Duplicate Individual Case Safety ReportsDrug Safety, 2014
- vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality IssuesDrug Safety, 2013
- Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilanceJournal of Public Health, 2013
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Quantitative signal detection using spontaneous ADR reportingPharmacoepidemiology and Drug Safety, 2009
- Data Quality Management in PharmacovigilanceDrug Safety, 2004